Skip to main content
SpringerLink
Log in

Caspofungin

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Caspofungin is the first in a new class of antifungal agents, the glucan synthesis inhibitors, that interfere with fungal cell wall synthesis.

  • ▴ Caspofungin exhibited in vitro and in vivo efficacy against a wide range of fungi and yeasts including Aspergillus and Candida species.

  • ▴ A complete or partial response to caspofungin therapy was seen in 40.7% of immuno-compromised adults with invasive aspergillosis who did not respond to, or did not tolerate, other antifungal agents in a noncomparative multi-centre study.

  • ▴ Caspofungin was effective in patients with oropharyngeal or oesophageal candidiasis, according to the preliminary results of 2 randomised double-blind trials.

  • ▴ Caspofungin was generally well tolerated in a multicentre noncomparative trial involving patients with invasive aspergillosis. One or more drug-related clinical adverse effects were experienced by 13.8% of caspofungin recipients (the most common were fever, nausea, vomiting and complications associated with the vein into which caspofungin was infused). The tolerability of caspofungin appeared to be better than that of amphotericin B and similar to that of fluconazole in double-blind, randomised trials involving patients with mucosal candidiasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5(2): 120–35

    Article  PubMed  CAS  Google Scholar 

  2. De Pauw BE, Donnelly JP, Verweij PE, et al. Current management of fungal infections in immunocompromised patients and polyene lipid complexes for treatment of invasive fungal infection. J Infect Dis Antimicrob Agents 1998 May–Aug; 15: 85–96

    Google Scholar 

  3. Maertens JA, Boogaerts MA. Fungal cell wall inhibitors: Emphasis on clinical aspects. Current Pharmaceutical Design 2000; 6(2): 225–39

    Article  PubMed  CAS  Google Scholar 

  4. Scott Hicks P, Dorso K, Gerckens L, et al. Comparative in vitro susceptibility of clinical trial isolates to the glucan synthesis inhibitor antifungal caspofungin (Cancidas™, MK-0991) [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18; Toronto

  5. Flattery AM, Scott Hicks P, Wilcox A, et al. In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the glucan synthesis inhibitor caspofungin acetate (Cancidas™, MK-0991) [poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18; Toronto

  6. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 Oct; 36: 2950–6

    PubMed  CAS  Google Scholar 

  7. Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium. isolates [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26: 546

    Google Scholar 

  8. Pfaller MA, Marco F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium., Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998 Apr; 30: 251–5

    Article  PubMed  CAS  Google Scholar 

  9. Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy studies with caspofungin and amphotericin B against Aspergillus and Fusarium. [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18; Toronto, 368

  10. Barchiesi F, Schimizzi AM, Fothergill AW, et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999 Apr; 18: 302–4

    PubMed  CAS  Google Scholar 

  11. Bachmann SP, Perea S, Kirkpatrick WR, et al. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18; Toronto, 352

  12. Cohen S, Carroll K. In vitro evaluation of pneumocandin activity against clinical isolates of yeasts [abstract]. 99th General Meeting American Society for Microbiology; 1999 May 30, 138

  13. Marco F, Pfaller MA, Messer SA, et al. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998 Sep; 32: 33–7

    Article  PubMed  CAS  Google Scholar 

  14. Espinel-Ingroff A. In vitro studies with L-743,872, a water soluble pneumocandin: a comparative study [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 105

  15. Vazquez JA, Lynch M, Boikov D, et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997 Jul; 41: 1612–4

    PubMed  CAS  Google Scholar 

  16. Vazquez JA, Boikov D, Lynch ME, et al. In-vitro antifungal activity of L-743,872, a new penumocandin, against sensitive and resistant Torulopsis and Candida species [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 105

  17. Scott PM, Gerckens L, Lynch L, et al. Comparative in vitro susceptibility of clinical trial isolates to the echinocandin antifungal MK-991 [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25–27; San Diego, 452

  18. Pfaller MA, Messer SA, Gee S, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999 Mar; 37: 870–2

    PubMed  CAS  Google Scholar 

  19. Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997 Sep; 41: 1957–60

    PubMed  CAS  Google Scholar 

  20. Nelson PW, Lozano-Chiu M, Rex JH. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J Med Vet Mycol 1997 Jul–Aug; 35: 285–7

    Article  PubMed  CAS  Google Scholar 

  21. Del-Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997 Aug; 41: 1835–6

    PubMed  CAS  Google Scholar 

  22. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997 Nov; 41: 2333–8

    PubMed  CAS  Google Scholar 

  23. Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000 Sep; 44: 2310–8

    Article  PubMed  CAS  Google Scholar 

  24. Bernard EM, Ishimaru T, Armstrong D. Low doses of the pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulmonary aspergillosis [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 106

  25. Graybill JR, Bocanegra R, Luther M, et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 1997 Sep; 41: 1937–9

    PubMed  CAS  Google Scholar 

  26. Graybill JR, Najvar LK, Luther MF, et al. Treatment of murine disseminated candidiasis with L-743, 872. Antimicrob Agents Chemother 1997 Aug; 41: 1775–7

    PubMed  CAS  Google Scholar 

  27. Flattery AM, Abruzzo GK, Smith JG, et al. Activity of pneumocandin L-743872 in a CD4+ T-cell deficient mouse model of oropharyngeal and gastrointestinal candidiasis [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 106

  28. Smith JG, Abruzzo GK, Gill CJ, et al. Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 107

  29. Bartizal K, Smith JG, Gill CJ, et al. Preclinical efficacy of MK-0991 in pancytopenic mouse models of disseminated candidiasis and aspergillosis [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28; Toronto, 159

  30. Graybill JR, Najvar LK, Montalbo EM, et al. Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother 1998 Jan; 42: 151–3

    PubMed  CAS  Google Scholar 

  31. Kohler S, Wheat LJ, Connolly P, et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000 Jul; 44: 1850–4

    Article  PubMed  CAS  Google Scholar 

  32. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998 Aug; 42: 1985–9

    PubMed  CAS  Google Scholar 

  33. Stone JA, Holland SD, Ju WD, et al. Single- and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25–27; San Diego, 83

  34. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997 Nov; 41: 2339–44

    PubMed  CAS  Google Scholar 

  35. Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000 Nov; 28: 1274–8

    PubMed  CAS  Google Scholar 

  36. Merck & Co. Cancidas® (caspofungin acetate) prescribing information. Merck & Co. Available from: URL: http://www.merck.com [Accessed 2001 Mar 16]

  37. Stone JA, Ballow CH, Holland S, et al. Single dose caspofungin pharmacokinetics in healthy elderly subjects [poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18, Toronto

  38. Maertens J, Raad I, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (lipid AMB), or azoles [poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18; Toronto

  39. Sable CA, Villanueva A, Arathon E, et al. A randomized, double-blind, multicenter trial of MK-991 vs. amphotericin B in the treatment of Candida esophagitis in adults [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28–Oct 1; Toronto, 15

  40. Arathoon E, Gotuzzo E, Noriega L, et al. A randomized, double-blind, multicenter trial of MK-0991, an echinocandin antifungal agent, vs amphotericin B for the treatment of oropharyngeal and esophageal candidiasis in adults [abstract]. Clin Infect Dis 1998 Oct; 27: 939

    Google Scholar 

  41. Sable CA, Nguyen BY, Chodakewitz JA, et al. Safety of caspofungin acetate (CA) in the treatment of fungal infections [poster]. Focus on Fungal Infections 11; 2001 Mar 14–16; Washington DC

    Google Scholar 

  42. Stone JA, McCrea J, Wickersham P, et al. A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen [poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 18; Toronto

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Gillian M. Keating & Blair Jarvis

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blair Jarvis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M., Jarvis, B. Caspofungin. Drugs 61, 1121–1129 (2001). https://doi.org/10.2165/00003495-200161080-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161080-00007

Keywords

Search

Navigation